vip 77

Sowei 2025-01-13
Dublin, Dec. 23, 2024 (GLOBE NEWSWIRE) -- The "Burkitt Lymphoma - Global Clinical Trials Review, 2024" has been added to ResearchAndMarkets.com's offering. The clinical trial report provides an overview of Burkitt Lymphoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Burkitt Lymphoma. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. The clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Report Scope The report provides a snapshot of the global clinical trials landscape Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment The Report provides enrollment trends for the past five years Report provides latest news for the past three months Reasons to Buy Assists in formulating key business strategies with regards to investment Helps in identifying prominent locations for conducting clinical trials which saves time and cost Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities Supports understanding of trials count and enrollment trends by country in global therapeutics market Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials Facilitates clinical trial assessment of the indication on a global, regional and country level Key Topics Covered: Clinical Trials Report Coverage Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Five Countries Contributing to Clinical Trials in Asia-Pacific Top Five Countries Contributing to Clinical Trials in Europe Top Countries Contributing to Clinical Trials in North America Top Five Countries Contributing to Clinical Trials in Middle East and Africa Top Countries Contributing to Clinical Trials in Central and South America Clinical Trials by G7 Countries: Proportion of Burkitt Lymphoma to Oncology Clinical Trials Clinical Trials by Phase in G7 Countries Clinical Trials in G7 Countries by Trial Status Clinical Trials by E7 Countries: Proportion of Burkitt Lymphoma to Oncology Clinical Trials Clinical Trials by Phase in E7 Countries Clinical Trials in E7 Countries by Trial Status Clinical Trials by Phase In Progress Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Subjects Recruited Over a Period of Time Clinical Trials by Sponsor Type Prominent Sponsors Top Companies Participating in Burkitt Lymphoma Therapeutics Clinical Trials Prominent Drugs Clinical Trial Profile Snapshots Abbreviations Company Coverage: Bristol-Myers Squibb Co Pfizer Inc Takeda Pharmaceutical Co Ltd Roche Holding AG Amgen Inc Gilead Sciences Inc Merck & Co Inc Novartis AG Sanofi Sian Wuhan Medical Technology Co Ltd For more information about this clinical trials report visit https://www.researchandmarkets.com/r/c5m5c6 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.vip 77

America’s future depends on a thriving free press, and it’s time we take it backTruist Finl's TFC short percent of float has risen 41.67% since its last report. The company recently reported that it has 17.98 million shares sold short , which is 1.36% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.34 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish. See Also: List of the most shorted stocks Truist Finl Short Interest Graph (3 Months) As you can see from the chart above the percentage of shares that are sold short for Truist Finl has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted. Comparing Truist Finl's Short Interest Against Its Peers Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis. According to Benzinga Pro , Truist Finl's peer group average for short interest as a percentage of float is 3.74%, which means the company has less short interest than most of its peers. Did you know that increasing short interest can actually be bullish for a stock? This post by Benzinga Money explains how you can profit from it. This article was generated by Benzinga's automated content engine and was reviewed by an editor. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Justice Doesn’t Happen by Accident

( MENAFN - GlobeNewsWire - Nasdaq) WASHINGTON, D.C., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Today, the Minority Business Development Agency (MBDA) released its Ways in Which Minority Business Enterprises (MBEs) Can Meet Gaps in the U.S. supply chain report. This report presents several avenues for MBEs to meet gaps in the U.S. supply chain and discusses opportunities to conduct, commission, and collaborate on new studies with other federal, state, and private institutions on this topic. This report offers a data-driven snapshot of the MBE supplier landscape, analyzing representation of MBE firms in both manufacturing industries and the service industries that support manufacturing. The data shows there is room to grow representation of MBEs, particularly in manufacturing. The report identifies barriers present in supply chains for MBE participation; and the ways in which policy makers, technical assistance providers, and large corporations can utilize MBEs to advance the U.S. supply chain. “MBDA has embarked on a new chapter of our long and proud history to serve and support MBEs,” said Deputy Under Secretary of Minority Business Development Eric Morrissette .“The Minority Business Development Act of 2021 empowered our agency to work toward equity among U.S. firms and strengthen our national economy, and we are forever committed to that mission. Together with public and private sector partners, we will continue to address capital access disparities and highlight sources of alternative financing while closing gaps in the U.S. supply chain.” The report highlights many public and private initiatives directed toward promoting the success of MBEs in supply chain industries and breaking down barriers. Increasing MBE participation in advanced technologies and manufacturing relies on a range of initiatives to ensure MBEs can develop the capacities and skills needed to compete in rapidly changing markets. The report recommends four potential opportunities through which MBEs can help close supply chain gaps through policy and business plan changes: Other suggestions made in the report include addressing unique challenges by MBE demographic groups and expanding qualitative data gathering to learn about the needs of MBEs in manufacturing. This report was mandated under the Minority Business Development Act of 2021. The Act codified MBDA and many of its existing programs. The report, and details of its findings, can be reviewed at . About the Minority Business Development Agency (MBDA): The U.S. Department of Commerce, Minority Business Development Agency is the only Federal agency dedicated to the growth and global competitiveness of U.S. minority business enterprises (MBEs). For more than 50 years, MBDA's programs and services have better equipped MBEs to create jobs, build scale and capacity, increase revenues, and expand regionally, nationally, and internationally. ### Attachment MENAFN20122024004107003653ID1109018323 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

COLLEGE BOWLKendrick Lamar's Tribute To Tupac Shakur, Snoop Dogg Recall In 'GNX' Album | WATCH

Pakistan will move ahead of India by...? How is Islamabad boosting its air power despite crumbling economy?‘We don’t want to be too stuffy’: New Powerhouse boss on what we can expect

TIME’s Best Photos of 2024Antimicrobial resistance (AMR) in waterways presents a critical threat . If commonly used antibiotics are deemed useless, decades of progress in human medicine and agriculture could be undermined. By 2050, AMR could cause 10 million deaths annually, according to the UN Environment Programme . But AMR is not just a human health issue. It also contributes to a decline in water quality and is exacerbated by water pollution, particularly from sources such as sewage and agricultural runoff. So, it’s a significant environmental concern with far-reaching implications. Addressing AMR in water is challenging because water systems are complex and can carry many different types of resistant bacteria. The lack of efficient, scalable and globally accessible methods to monitor AMR in water makes it difficult to mitigate this growing threat. I recently published a review in the Sustainable Microbiology journal that identifies key trends in AMR detection methods and highlights significant gaps. Rivers, lakes and wastewater systems around the world act as reservoirs and pathways for resistant superbugs and their genes, allowing AMR to spread across ecosystems, affecting wildlife, agriculture and human populations. River water is the most studied source of water samples, making up 42% of AMR-related research studies. Other water sources, including lakes and wastewater, may also play a key role in spreading resistant genes but, without detailed analysis, will remain misunderstood. Most AMR research comes from three countries: the US (17%), China (10%) and Brazil (9%). This shows where the focus is, but many other regions, especially low-income countries, are not well studied. This is concerning because AMR may be even more serious in these areas, yet data is lacking. To detect AMR, scientists primarily use two advanced molecular methods: polymerase chain reaction (PCR) (used in 57% of studies) and metagenomics (27%), alongside traditional culture-based methods that involve growing bacteria in a lab. Culture-based methods are simpler and cheaper than molecular methods but cannot be used onsite. They also can’t detect dead bacteria or hidden resistance genes. PCR amplifies specific DNA sequences for detection and can be used to identify specific bacteria. Metagenomics is a technique that analyses all of the genetic material from entire microbial communities within a sample, offering a broader perspective. These advanced methods are better at detecting AMR in rivers, lakes and oceans. They can find both known and new types of resistance, making them more useful for thorough monitoring. In Brazil , scientists used metagenomics to search for all of the different resistance genes present in waterways in different cities. This technique can detect patterns of resistance that regular tests can’t. While these methods are time-consuming and complicated (because they need specialised equipment and trained staff) and can be expensive, costing thousands of euros, they could be used more widely if funding is available. This would help track antibiotic resistance around the world, making it easier to find and fight. One Europe-wide study shows that culture methods failed to find all the resistance genes in contaminated river systems in ten countries, while advanced metagenomic techniques were able to identify them. So, molecular tools are crucial for understanding the true extent of AMR. My review shows a shift towards molecular techniques as the gold standard for AMR detection. It highlights the inadequacies of traditional culture-based methods and the need for integrated approaches that combine molecular techniques such as PCR (for detecting specific resistance genes) with metagenomics (for broader microbial community analysis). For example, wastewater monitoring programs could use PCR to quickly identify key resistance genes in hotspots while employing metagenomics to map the diversity of resistant organisms. This would offer a more balanced approach that optimises cost, efficiency, and accessibility. A hybrid approach By mapping global research efforts, I identified underrepresented regions such as sub-Saharan Africa and southeast Asia. I also found that certain water sources were underrepresented, particularly rivers in low-income countries. Without more equitable and comprehensive AMR surveillance, those will not be accounted for. To make accurate AMR detection more accessible to all, hybrid approaches that combine the comprehensive detection capabilities of molecular methods with the affordability of culture-based methods will be essential. Governments around the world must prioritise investments in technologies that are not only scientifically robust but also economically viable, particularly for low- and middle-income countries. New methods such as PCR and metagenomics can help us fight the spread of drug resistance. If we can make these methods cheaper and easier to use it could help us manage wastewater better, improve global tracking of drug resistance and make decisions that protect both people and the environment from superbugs. Don’t have time to read about climate change as much as you’d like? Get a weekly roundup in your inbox instead. Every Wednesday, The Conversation’s environment editor writes Imagine, a short email that goes a little deeper into just one climate issue. Join the 40,000+ readers who’ve subscribed so far.Century-old department store Nordstrom has agreed to be acquired and taken private by Nordstrom family members and a Mexican retail group in a $6.25 billion deal with the industry being squeezed by discount chains and other competition. Public companies are under a lot more scrutiny and if private, Nordstrom may have more leeway in reviving a department store chain that has been attempting to reinvigorate sales for years. Nordstrom shareholders will receive $24.25 in cash for each share of Nordstrom common stock, or about $4 billion in all, representing a 42% premium on the company's stock as of March 18, when reports of a potential transaction was reported by the media. The acquiring group will also pick up more than $2 billion in Nordstrom debt. The traditional department stores have suffered in the face of withering competition from giants like Walmart and Target, as well as a host of fast-fashion bands and Amazon.com. Nordstrom rivals Macy's and Kohl's have been pressured by major investors to make huge changes in order to return more profit to shareholders. RELATED: Inside the empty flagship Nordstrom in San Francisco, closing after more than 3 decades Sales at Nordstrom have essentially flatlined over the past decade or so and it announced last year that it was closing all of its Canadian stores and cutting 2,500 jobs as it winds down operations in the country. Nordstrom first announced plans to expand to Canada in 2012 and opened its first store in Calgary at CF Chinook Centre in September 2014. The offer announced Monday tops the previous $23-per-share bid that the Nordstrom family and Mexican retail group, El Puerto de Liverpool, made in September. The board also plans to authorize a special dividend of up to 25 cents per share, based on Nordstrom's cash on hand immediately prior to and contingent on the close of the transaction. The deal is expected to close in the first half of 2025, at which time the company's shares will no longer trade publicly. "While a change in ownership does not automatically remedy all of the problems with the department store operation, it will allow the family and their backers to take a long-term view of the business and make necessary investments and changes away from the short-term scrutiny of public markets," wrote Neil Saunders, Managing Director of GlobalData, in a note to clients. Nordstrom's board of directors unanimously approved the the proposed transaction, with members Erik and Pete Nordstrom, part of the Nordstrom family taking over the company - recusing themselves from that vote. Following the close of the transaction, the Nordstrom family will have a majority ownership stake in the company. Erik and Pete Nordstrom are the fourth-generation leadership at the Seattle retailer, which was founded in 1901 as a shoe store. Erik is the company's chief executive and Peter is president. After opening 23 new stores so far this year, the company now operates a combined 381 Nordstrom and Nordstrom Rack stores in the U.S. Nordstrom shares fell about 1.5% Monday, but they are up 34% this year on rumors of a family takeover. The company's stock is still down considerably from post-pandemic highs above $40 per share. In May of this year, Bruce Nordstrom, a retail executive who helped expand his family's Pacific Northwest department store chain into an upscale national brand, died at age 90. He was one of several Nordstrom family members who in 2017 made a push to take the company private, proposing to buy out the 70% of the department store's stock they didn't already own. Those talks failed in 2018 but earlier this year, his sons started another series of buyout negotiations, leading to Monday's announcement.

0 Comments: 0 Reading: 349
You may also like